SCHEMBL3015116

SCHEMBL3015116

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4Cl)CC3)n2)c1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MAPT P10636 4/20 0.52
MEN1 O00255 3/20 0.52
LMNA P02545 2/20 0.52
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPK1 P28482 2/20 0.48
CHRM4 P08173 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
TP53 P04637 1/20 0.43
AR P10275 1/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GBA1 P04062 2/20 0.42
FAAH O00519 1/20 0.41
EPHX2 P34913 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008326 0.93 LMNA (0.48) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3002043 0.93 KMT2A (0.52) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3014970 0.89 AR (0.45) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3012852 0.89 AR (0.47) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3013471 0.89 KMT2A (0.51) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3011983 0.89 KMT2A (0.54) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3003930 0.88 MAPT (0.46) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3010819 0.88 KMT2A (0.52) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3011733 0.88 SMN1; SMN2 (0.52) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL3014561 0.88 MEN1 (0.44) KMT2AMAPTMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MAPT 18/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.